Fluxion Biosciences, a provider of cellular analysis tools for use in life science research and drug discovery applications, announced in December the expansion of its sales and service network into Asia.
ALA brings even more new offerings to LabAutomation2010 in Palm Springs, to advance knowledge among all types of laboratory
professionals at all levels
Thermo Fisher Scientific Inc. also announced in December a collaboration between its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and Expression Pathology Inc.
GE Healthcare has launched FTA DMPK cards for the collection and storage of blood samples for use in pharmacokinetic and toxicokinetic (PK/TK) studies.
BioTek Instruments Inc. has expanded its Synergy Multi-Mode Microplate Reader family with the introduction of the patent-pending Synergy H4 with Hybrid Technology.
he Swiss branches of Pfizer Inc., Eli Lilly & Co. and Bayer AG were fined a total of $5.7 million by competition regulators on Dec. 1 for alleged price-fixing of drugs for erectile dysfunction.
President Barack Obama on Dec. 8 issued a directive specifying actions that should be taken to make government agencies better able to engage with the public, including plans to make data and information from federally funded research available for public access.
With life sciences evolving so quickly, bioinformatics research is critical to building information infrastructures that can match that evolution, allow researchers to access data quickly and easily and develop new informatics tools as needed. It is no longer enough to generate the best measurement data; researchers also require the best meaning and insight from that data.
We just left behind both a year and a decade, and pundits can’t resist opining on what happened. We had few good days early in this millennium, but we’ve got 990 years to make up for it.
Beginning this issue, our Government Watch section will profile some of the latest legal, legislative, and regulatory developments in the pharma/biotech arenas. In our first month of coverage, we had a veritable grab-bag of stories to sink our teeth into, and settled on a wide range of topics to show our readers the various forms government scrutiny can take: federal oversight, state legislation, state regulation and international regulation, to name a few. Our writers—who are no strangers to reporting on such matters—were eager to hit the ground running and delve into these topics, but were met with an all-too-familiar roadblock: Fear.
With private equity firm Telegraph Hill Partners (THP) acting as the honest broker, NEXUS Biosystems Inc. announced in December its acquisition of Aurora Biotechnologies.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.